全文获取类型
收费全文 | 306篇 |
免费 | 16篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 6篇 |
妇产科学 | 5篇 |
基础医学 | 58篇 |
口腔科学 | 3篇 |
临床医学 | 24篇 |
内科学 | 75篇 |
皮肤病学 | 3篇 |
神经病学 | 46篇 |
特种医学 | 5篇 |
外科学 | 20篇 |
综合类 | 6篇 |
一般理论 | 2篇 |
预防医学 | 14篇 |
眼科学 | 1篇 |
药学 | 43篇 |
肿瘤学 | 6篇 |
出版年
2021年 | 4篇 |
2020年 | 3篇 |
2019年 | 14篇 |
2018年 | 8篇 |
2017年 | 3篇 |
2015年 | 6篇 |
2014年 | 13篇 |
2013年 | 12篇 |
2012年 | 26篇 |
2011年 | 10篇 |
2010年 | 11篇 |
2009年 | 17篇 |
2008年 | 13篇 |
2007年 | 18篇 |
2006年 | 11篇 |
2005年 | 11篇 |
2004年 | 9篇 |
2003年 | 13篇 |
2002年 | 18篇 |
2001年 | 4篇 |
2000年 | 14篇 |
1999年 | 6篇 |
1998年 | 3篇 |
1996年 | 5篇 |
1995年 | 3篇 |
1993年 | 2篇 |
1992年 | 4篇 |
1991年 | 6篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 4篇 |
1986年 | 4篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1970年 | 8篇 |
1968年 | 2篇 |
1967年 | 2篇 |
1966年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有323条查询结果,搜索用时 15 毫秒
1.
The delivery of particles as small as possible (preferably <5 µm) to the respiratory tract should be the aim of those formulating metered dose inhalers (MDIs). This may be facilitated by the formulation of solution, rather than suspension-type, pressurized aerosol units. Two series of MDIs were compared; one contained suspended micronized disodium fluorescein (0.1%, w/v), while the other contained the same concentration of dissolved salicylic acid. Either oleic acid, L--phosphatidylcholine, or sorbitan trioleate was incorporated at 0.15% (w/v) as suspending agent (disodium fluorescein) or solubilizing agent (salicylic acid). The propellant blend was 70% (w/w) Freon 12 and 30% (w/w) Freon 11 in all cases. This exhibited a vapor pressure of 50.6 psig (444.7 kPa) at 21°C. The output particle size distribution of the aerosol reaching the cascade impactor showed a mass median aerodynamic diameter (MMAD) of approximately 4 and 2 µm for the suspension and solution formulations respectively, regardless of the surfactant used. Larger MMADs were observed for solution aerosols formulated with oleic acid (2.32 µm) compared to those containing L--phosphatidylcholine (1.93 µm) or sorbitan trioleate (2.07 µm). Possible reasons for these observations are discussed. 相似文献
2.
C. W. Ang K. Krogfelt P. Herbrink J. Keijser W. van Pelt T. Dalby M. Kuijf B. C. Jacobs M. P. Bergman P. Schiellerup C. E. Visser 《Clinical microbiology and infection》2007,13(9):915-922
Weeks or months following Campylobacter infection, a small proportion of infected individuals develop Guillain-Barré syndrome (GBS) or reactive arthritis (ReA). Stool culture for Campylobacter is often negative in these patients, and serology is therefore the method of choice for diagnosing a recent infection with Campylobacter. This study developed a capture ELISA system to detect anti-Campylobacter IgA and IgM antibodies indicative of a recent infection. The sensitivity of the assay was 82.0% in uncomplicated Campylobacter enteritis patients, 96.2% in GBS patients who were culture-positive for Campylobacter, and 93.1% in culture-positive ReA patients, with a specificity of 93.0%. The assay allows identification of Campylobacter infection in patients with post-infectious neurological and rheumatological complications. 相似文献
3.
4.
5.
Lawrence A. Leiter Deepak L. Bhatt Darren K. McGuire Hwee Teoh Kim Fox Tabassome Simon Shamir R. Mehta Eli I. Lev Róbert G. Kiss Anthony J. Dalby Héctor Bueno Wilhelm Ridderstråle Anders Himmelmann Jayne Prats Yuyin Liu Jane J. Lee John Amerena Mikhail N. Kosiborod Philippe Gabriel Steg 《Journal of the American College of Cardiology》2021,77(19):2366-2377
BackgroundTHEMIS (The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study) (n = 19,220) and its pre-specified THEMIS-PCI (The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study-Percutaneous Coronary Intervention) (n = 11,154) subanalysis showed, in individuals with type 2 diabetes mellitus (median duration 10.0 years; HbA1c 7.1%) and stable coronary artery disease without prior myocardial infarction (MI) or stroke, that ticagrelor plus aspirin (compared with placebo plus aspirin) produced a favorable net clinical benefit (composite of all-cause mortality, MI, stroke, fatal bleeding, and intracranial bleeding) if the patients had a previous percutaneous coronary intervention.ObjectivesIn these post hoc analyses, the authors examined whether the primary efficacy outcome (cardiovascular death, MI, stroke: 3-point major adverse cardiovascular events [MACE]), primary safety outcome (Thrombolysis In Myocardial Infarction–defined major bleeding) and net clinical benefit varied with diabetes-related factors.MethodsOutcomes were analyzed across baseline diabetes duration, HbA1c, and antihyperglycemic medications.ResultsIn THEMIS, the incidence of 3-point MACE increased with diabetes duration (6.7% for ≤5 years, 11.1% for >20 years) and HbA1c (6.4% for ≤6.0%, 11.8% for >10.0%). The relative benefits of ticagrelor plus aspirin on 3-point MACE reduction (hazard ratio [HR]: 0.90; p = 0.04) were generally consistent across subgroups. Major bleeding event rate (overall: 1.6%) did not vary by diabetes duration or HbA1c and was increased similarly by ticagrelor across all subgroups (HR: 2.32; p < 0.001). These findings were mirrored in THEMIS-PCI. The efficacy and safety of ticagrelor plus aspirin did not differ by baseline antihyperglycemic therapy. In THEMIS-PCI, but not THEMIS, ticagrelor generally produced favorable net clinical benefit across diabetes duration, HbA1c, and antihyperglycemic medications.ConclusionTicagrelor plus aspirin yielded generally consistent and favorable net clinical benefit across the diabetes-related factors in THEMIS-PCI but not in the overall THEMIS population. 相似文献
6.
7.
8.
Secretion of mucins from airway epithelial cells has been studied almost exclusively using in vitro cell culture systems. Our understanding of in vivo secretion is greatly limited due to the unavailability of both suitable model systems and adequate assays. It has been reported that ATP induces mucin release from the cultured primary tracheal surface epithelial cell, but there is no clear demonstration of the effect of ATP on mucin release in vivo, which is important to understand the mechanism of mucin release in vivo and also to devise means for regulation of mucin release. The objective of this experiment was to see if inhaled ATP could stimulate airway mucin release in intact rats using both enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry. The results were: (1) a new monoclonal antibody (mAbRT03) developed against purified rat mucins specifically recognized high-molecular-mass mucins; (2) ELISA results with conventional gel-filtration assay results are virtually superimposable; (3) inhalation of ATP in intact rats resulted in a dose-independent increase in the amount of mucins in the tracheal lavage fluid with a concomitant decrease in the number of mucin-positive cells in the trachea. We conclude that extracellular ATP can stimulate mucin release from the airway in vivo, and the present rat inhalation system combined with ELISA of the airway secretions should serve a useful model for studying the pharmacology of airway mucin secretion in vivo. 相似文献
9.
Dalby MC Davidson SJ Burman JF Sigwart U Davies SW 《Journal of thrombosis and thrombolysis》2002,13(3):141-145
Background: Abciximab reduces the thrombotic complications of angioplasty. It is also used, as a 'bail out' treatment when angioplasty is complicated by thrombus but its speed of action is not known. This study sought to establish how quickly abciximab blocks the aggregation of both quiescent and activated platelets to explain this rapid efficacy.
Methods: Optical aggregometry (OA) and whole blood electrical impedance platelet aggregometry (WBEA) were performed with blood from 10 healthy volunteers. Abciximab 5 g/ml was added in each case with saline control 5 minutes before agonist, 10 seconds before agonist and during aggregation.
Results: (1) Abciximab administered 5 minutes before agonist, completely inhibited aggregation with OA: (medians and ranges) 0% (all 0), control: 71% (50–95%) p < 0.001. and with WBEA: 0 (all 0 ), control: 7.5 (4.8–12.5 ) p = 0.016. (2) When administered 10 s before agonist with OA a small initial degree of aggregation occurred but this was rapidly reversed (time to reversal: 2 mins (1–4.5 mins) to low levels of aggregation 16.5% (0–22%), control 72.5% (55–95%) p = 0.002. With WBEA aggregation was completely inhibited: 0 (all 0 ), control: 7.5 (4.8–12.3 ) p = 0.016. (3) When administered during aggregation, with OA the rise in the aggregometry tracing was rapidly arrested (time to arrest: 1.5 mins (0.1–3 mins)) with no further aggregation occurring: 42% (30–57%), control: 80% (60–100%) p = 0.002. With WBEA the findings were similar: (time to arrest 1.5 mins (1–2 mins)) 6.3 (1.5–11.3 ), control: 10 (3–12 ) p = 0.031.
Conclusions: These data suggest that when administered during a procedure in which thrombus has occurred, aggregation may be rapidly arrested. This applies to quiescent platelets but also activated platelets undergoing aggregation. 相似文献
10.